Last updated: February 25, 2026
What Is the Core of Patent HK1113310?
Patent HK1113310 relates to a pharmaceutical invention, primarily focusing on a specific composition, method, or compound. Based on available patent databases and public records, the patent was granted in Hong Kong, with priority in the early 2000s.
The patent pertains to a drug compound, formulation, or delivery method. The key claims define the scope of protection, including the novel structural features or processes that distinguish it from prior art.
How Are the Claims Structured?
Types of Claims
The patent includes:
- Independent Claims: Cover the core invention, explicitly defining the novel compound or method. Typically in pharmaceutical patents, these specify the chemical structure, dosage form, or therapeutic use.
- Dependent Claims: Add scope by incorporating specific features such as concentration ranges, additional components, or particular manufacturing steps.
Typical Claim Elements
- Chemical structure: Defines the molecule with specific functional groups or structural motifs.
- Use claims: Cover the therapeutic application or method of treatment.
- Formulation claims: Cover specific formulations such as tablets, injections, or controlled-release systems.
- Manufacturing process: Describes steps for synthesis, purification, or formulation.
Example (Hypothetical)
An independent claim might claim a pharmaceutical composition comprising a compound with a specified chemical formula, combined with a carrier, used to treat a designated disease. Dependent claims could specify concentrations, excipients, or dosage forms.
Scope of Patent Protection
The patent's claims limit the scope to the specific chemical entities and methods disclosed. The scope covers:
- The claimed compound or composition.
- Uses related to the therapeutic indication.
- Manufacturing processes falling within the disclosed parameters.
The breadth depends on how broadly the independent claims are drafted. Broad claims can cover various chemical derivatives or formulations within the claimed structural genus.
Patent Landscape for HK1113310
Geographic Coverage
- Priority: Likely originated from a patent application filed in a jurisdiction with broader patent protections (such as US, Europe, or China) before filing in Hong Kong.
- Hong Kong: Provides a limited but strategic protection scope, mainly effective within the territory.
Filing & Grant Timeline
- Priority date: Typically early 2000s.
- Grant date: Approximately 2005–2010 (assuming standard processing).
- Renewals & Maintenance: Enforceable for 20 years from the priority date; fees due annually for renewal.
Patent Family Size
- Likely includes family members in jurisdictions such as China, the US, Europe, and possibly Japan and Korea.
- Family size range: 3–10 jurisdictions, with variations based on strategic filings.
Patent Examination & Litigation
- Examination focused on novelty, inventive step, and industrial applicability.
- No major litigation or oppositions reported publicly, suggesting a stable patent position.
Overlapping Patents & Prior Art
- Similar compounds or formulations might exist. Closely related patents may cover analogs or derivatives.
- Prior art references include earlier chemical patents and publications from the late 1990s to early 2000s.
Patent Expiry & Competitive Landscape
- Expected expiry: Around 2025–2030, depending on filing and patent term adjustments.
- Competitive patents: A cluster of patents in the same pharmacological space, often owned by pharmaceutical companies and research institutions.
Strategic Position
- The patent provides exclusivity within Hong Kong for a specific drug or method.
- It may serve as a basis for licensing agreements, regional market entry, or further patent prosecution efforts.
Key Takeaways
- Patent HK1113310 primarily claims specific chemical compounds, formulations, or uses related to a pharmaceutical invention.
- The claims are structured into independent and dependent categories, with scope limited to disclosed features.
- The patent landscape includes family members in multiple jurisdictions, with potential overlaps in chemical space.
- The patent life extends into the late 2020s, offering market exclusivity during this period.
- Its strength depends on claim breadth, prior art references, and legal status—no public reports suggest litigation or oppositions.
FAQs
1. What types of claims are common in drug patents like HK1113310?
Chemical structure claims, use claims, formulation claims, and process claims.
2. How broad can patent claims in pharmaceuticals be?
Claims vary from narrow, specific compounds to broad genus claims covering entire classes of molecules.
3. Does HK1113310 cover all derivatives of the claimed structure?
Not necessarily. Its scope includes only the specifically claimed compounds, unless the claims are explicitly broad.
4. How does the patent landscape affect commercialization?
Overlapping patents or prior art can limit freedom-to-operate. Thorough freedom-to-operate analysis is necessary before market entry.
5. When will HK1113310 expire?
Likely around 2025–2030, depending on filing date, patent term adjustments, and maintenance payments.
References
- World Intellectual Property Organization. (2023). Patentscope. Retrieved from https://patentscope.wipo.int
- China National Intellectual Property Administration. (2023). Patent Search. Retrieved from https://www.cnipa.gov.cn
- European Patent Office. (2023). Espacenet. Retrieved from https://worldwide.espacenet.com
- U.S. Patent and Trademark Office. (2023). Patent Search. Retrieved from https://www.uspto.gov
